Roche’s marketing applications for review of OCREVUS® (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Takeda walks away from cell therapy in priority U-turn

Taysha Says FDA Grants Breakthrough Therapy Designation To In Rett Syndrome

Intravitreal Injection of Retinal Progenitor Cells Shows Promise in Preclinical Study for Diabetic Retinopathy

Mercury Bio Reports Positive Results from Preclinical Study Evaluating Novel Drug Delivery Technology Transporting Protein